Immunomodulation associated with clinical and MRI worsening in patients with progressive MS treated with MD1003 (high dose pharmaceutical grade biotin)

被引：0
|
作者：
Pignolet, B. [1 ,2 ]
Ciron, J. [1 ]
Bucciarelli, F. [1 ,2 ]
Scandella, L. [1 ,2 ]
Biotti, D. [1 ]
Lerebours, F. [1 ]
Dorcet, G. [1 ,2 ]
Rabadeux, C. [1 ]
Freitas, N. [1 ]
Bonneville, F. [3 ]
Brassat, D. [1 ,2 ]
机构：
[1] CHU Toulouse, Hop Pierre Paul Riquet, CRC SEP, Pole Neurosci, Toulouse, France
[2] Univ Toulouse, UMR U1043, Toulouse, France
[3] CHU Toulouse, Hop Pierre Paul Riquet, Serv Radiol, Toulouse, France
来源：
MULTIPLE SCLEROSIS JOURNAL | 2018年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P878
引用
收藏
页码：467 / 468
页数：2
相关论文
共 50 条
  • [1] Real-world effectiveness of MD1003 (high dose pharmaceutical grade biotin) in patients with progressive MS
    Faure, J.
    Jauffret, J.
    Carreau, C.
    Legrain, P.
    Castex, C.
    Tourbah, A.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 281 - 282
  • [2] Treatment of progressive MS with MD1003 (high dose pharmaceutical grade biotin): real-world evidence
    Ciron, J.
    Pignolet, B.
    Bucciarelli, F.
    Biotti, D.
    Lerebours, F.
    Dorcet, G.
    Rabadeux, C.
    Freitas, N.
    Bonneville, F.
    Brassat, D.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 693 - 693
  • [3] Biomarkers of treatment response in patients with progressive multiple sclerosis treated with high-dose pharmaceutical-grade biotin (MD1003)
    Collongues, Nicolas
    Kuhle, Jens
    Tsagkas, Charidimos
    Lamy, Julien
    Meyer, Nicolas
    Barro, Christian
    Parmar, Katrin
    Amann, Michael
    Wuerfel, Jens
    Kappos, Ludwig
    Moreau, Thibault
    Seze, Jerome
    [J]. BRAIN AND BEHAVIOR, 2021, 11 (02):
  • [4] Results of the Phase 3 SPI2 Study of MD1003 (high dose Pharmaceutical grade Biotin) in Progressive MS
    Cree, Bruce A. C.
    Cutter, Gary
    Wolinsky, Jerry S.
    Freedman, Mark S.
    Comi, Giancarlo
    Giovannoni, Gavin
    Hartung, Hans-Peter
    Sedel, Frederic
    Lublin, Fred
    [J]. NEUROLOGY, 2020, 94 (15)
  • [5] High dose pharmaceutical grade biotin, MD1003, treatment preserves motor performance in a model of progressive neurodegeneration
    Nessler, S.
    Winkler, A.
    van der Meer, F.
    Gargareta, S.
    Cobos, A.
    Stadelmann, C.
    Nave, K. A.
    Brueck, W.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 311 - 311
  • [6] Efficacy and safety results of the phase 3 SPI2 study of MD1003 (high dose Pharmaceutical grade Biotin) in progressive MS
    Cree, B. A. C.
    Cutter, G.
    Wolinsky, J. S.
    Freedman, M. S.
    Comi, G.
    Giovannoni, G.
    Hartung, H. -P.
    Sedel, F.
    Lublin, F.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 46 - 46
  • [7] Effect of MD1003 (high dose pharmaceutical grade biotin) for the treatment of progressive MS: 48-month follow-up data
    De Seze, J.
    Edan, G.
    Moreau, T.
    Brochet, B.
    Sedel, F.
    Tourbah, A.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 287 - 288
  • [8] Annual Relapse Rates (ARR) in Patients with Spinal Progressive Multiple Sclerosis Treated with MD1003 (High-Dose Pharmaceutical Biotin)
    Morteau, Olivier
    Lasser, Robert
    Sedel, Frederic
    Brion, Guillaume
    Tourbah, Ayman
    Simon, Olivier
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 31 - 31
  • [9] Effect of MD1003 (high dose Pharmaceutical grade Biotin) in the Treatment of Progressive MS: Earlier Treatment Results in Lower Disability Over 48 Months
    De Seze, Jerome
    Edan, Gilles
    Moreau, Thibault
    Brochet, Bruno
    Sedel, Frederic
    Tourbah, Ayman
    [J]. NEUROLOGY, 2019, 92 (15)
  • [10] Long term effect of MD1003 (high dose pharmaceutical grade biotin) in a cohort of patients with progressive non-active multiple sclerosis
    Donze, C.
    Guyot, M. A.
    Kwiatkowski, A.
    Hautecoeur, P.
    Massot, C.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 385 - 385
12345